Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Downgrades Myovant Sciences to Neutral, Raises Price Target to $27

Baird analyst Brian Skorney downgrades Myovant Sciences (NYSE:MYOV) from Outperform to Neutral and raises the price target from $20 to $27.
byBenzinga Newsdesk
October 24, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Brian Skorney downgrades Myovant Sciences (NYSE:MYOV) from Outperform to Neutral and raises the price target from $20 to $27.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts